La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
SMS Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 3/6
SMS Pharmaceuticals possède un total de capitaux propres de ₹5.4B et une dette totale de ₹2.8B, ce qui porte son ratio d'endettement à 52.4%. Son actif total et son passif total sont ₹10.3B et de ₹5.0B. L'EBIT de SMS Pharmaceuticals est ₹917.4M ce qui fait que son ratio de couverture des intérêts 4.2. Elle dispose de liquidités et de placements à court terme de ₹362.0M.
Informations clés
52.4%
Ratio d'endettement
₹2.81b
Dette
| Ratio de couverture des intérêts | 4.2x |
| Argent liquide | ₹362.03m |
| Fonds propres | ₹5.36b |
| Total du passif | ₹4.98b |
| Total des actifs | ₹10.34b |
Mises à jour récentes de la santé financière
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21
SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09
Recent updates
Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09Should You Take Comfort From Insider Transactions At SMS Pharmaceuticals Limited (NSE:SMSPHARMA)?
Nov 18The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 110% And Shareholders Are Boasting About It
Oct 28What Kind Of Shareholders Hold The Majority In SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Shares?
Oct 08Are Dividend Investors Getting More Than They Bargained For With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Dividend?
Sep 17Analyse de la situation financière
Passif à court terme: Les actifs à court terme de SMSPHARMA ( ₹5.3B ) dépassent ses passifs à court terme ( ₹3.3B ).
Passif à long terme: Les actifs à court terme de SMSPHARMA ( ₹5.3B ) dépassent ses passifs à long terme ( ₹1.7B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de SMSPHARMA ( 45.6% ) est considéré comme élevé.
Réduire la dette: Le ratio d'endettement de SMSPHARMA est passé de 42.4% à 52.4% au cours des 5 dernières années.
Couverture de la dette: La dette de SMSPHARMA n'est pas bien couverte par le flux de trésorerie opérationnel ( 17.9% ).
Couverture des intérêts: Les paiements d'intérêts de SMSPHARMA sur sa dette sont bien couverts par l'EBIT ( 4.2 x couverture).